These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 23735279)
1. Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates. Choi YS; Hou S; Choe LH; Lee KH J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jul; 930():129-35. PubMed ID: 23735279 [TBL] [Abstract][Full Text] [Related]
2. Multiple reaction monitoring assay based on conventional liquid chromatography and electrospray ionization for simultaneous monitoring of multiple cerebrospinal fluid biomarker candidates for Alzheimer's disease. Choi YS; Lee KH Arch Pharm Res; 2016 Mar; 39(3):390-7. PubMed ID: 26404792 [TBL] [Abstract][Full Text] [Related]
3. A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. Paterson RW; Heywood WE; Heslegrave AJ; Magdalinou NK; Andreasson U; Sirka E; Bliss E; Slattery CF; Toombs J; Svensson J; Johansson P; Fox NC; Zetterberg H; Mills K; Schott JM Transl Psychiatry; 2016 Nov; 6(11):e952. PubMed ID: 27845782 [TBL] [Abstract][Full Text] [Related]
4. Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Liu Y; Qing H; Deng Y Int J Mol Sci; 2014 May; 15(5):7865-82. PubMed ID: 24806343 [TBL] [Abstract][Full Text] [Related]
5. An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Hölttä M; Minthon L; Hansson O; Holmén-Larsson J; Pike I; Ward M; Kuhn K; Rüetschi U; Zetterberg H; Blennow K; Gobom J J Proteome Res; 2015 Feb; 14(2):654-63. PubMed ID: 25490617 [TBL] [Abstract][Full Text] [Related]
6. Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays. Schauer SP; Mylott WR; Yuan M; Jenkins RG; Rodney Mathews W; Honigberg LA; Wildsmith KR Alzheimers Res Ther; 2018 Nov; 10(1):118. PubMed ID: 30486870 [TBL] [Abstract][Full Text] [Related]
8. A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. Brinkmalm G; Sjödin S; Simonsen AH; Hasselbalch SG; Zetterberg H; Brinkmalm A; Blennow K Proteomics Clin Appl; 2018 Jan; 12(1):. PubMed ID: 29028155 [TBL] [Abstract][Full Text] [Related]
9. Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. Perrin RJ; Payton JE; Malone JP; Gilmore P; Davis AE; Xiong C; Fagan AM; Townsend RR; Holtzman DM PLoS One; 2013; 8(5):e64314. PubMed ID: 23700471 [TBL] [Abstract][Full Text] [Related]
10. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. Robinson RA; Amin B; Guest PC Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223 [TBL] [Abstract][Full Text] [Related]
11. MSQ: a tool for quantification of proteomics data generated by a liquid chromatography/matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry based targeted quantitative proteomics platform. Oh JH; Pan S; Zhang J; Gao J Rapid Commun Mass Spectrom; 2010 Feb; 24(4):403-8. PubMed ID: 20069694 [TBL] [Abstract][Full Text] [Related]
12. Proteome studies of CSF in AD patients. Davidsson P; Sjögren M Mech Ageing Dev; 2006 Feb; 127(2):133-7. PubMed ID: 16293296 [TBL] [Abstract][Full Text] [Related]
13. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Roher AE; Maarouf CL; Sue LI; Hu Y; Wilson J; Beach TG Biomarkers; 2009 Nov; 14(7):493-501. PubMed ID: 19863188 [TBL] [Abstract][Full Text] [Related]